BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Waters and BD’s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

  July 14, 2025

   · 

  23 min read
• Press Releases

  Antibiotic Resistance Market Forecast to Hit USD 12.86 Billion by 2032, Driven by Rising Rates of Drug-Resistant Infections | Coherent Market Insights

  July 14, 2025

   · 

  1 min read
• Press Releases

  U.S. Next-generation Sequencing Library Preparation Market Size to Surpass USD 2,237.13 Million by 2034

  July 14, 2025

   · 

  1 min read
• 

  Rare diseases

  Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome

  The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”

  July 14, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs

  Through its recently unveiled Priority Voucher program, the FDA seeks to accelerate the review process for companies that promise to keep prices down.

  July 14, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Depression

  After Three Strikes, Relmada Abandons Depression Drug Esmethadone 

  The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage trials.

  July 14, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Cancer Therapeutics Market Size Expected to Hit USD 469.38 Bn by 2034

  July 14, 2025

   · 

  1 min read
• Press Releases

  Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

  July 14, 2025

   · 

  4 min read
• Press Releases

  RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

  July 14, 2025

   · 

  8 min read
• 

  Neuroscience

  Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins

  Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.

  July 14, 2025

   · 

  2 min read

   · 

  Tristan Manalac